Last reviewed · How we verify
Oral Zonisamide Therapy
Zonisamide is an anticonvulsant that reduces neuronal excitability through multiple mechanisms including sodium and calcium channel blockade and carbonic anhydrase inhibition.
Zonisamide is an anticonvulsant that reduces neuronal excitability through multiple mechanisms including sodium and calcium channel blockade and carbonic anhydrase inhibition. Used for Epilepsy (adjunctive therapy for partial seizures), Generalized tonic-clonic seizures.
At a glance
| Generic name | Oral Zonisamide Therapy |
|---|---|
| Sponsor | Affiliated Hospital of Nantong University |
| Drug class | Anticonvulsant / Antiepileptic drug |
| Target | Voltage-gated sodium channels, T-type calcium channels, carbonic anhydrase |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Zonisamide blocks voltage-gated sodium and T-type calcium channels, reducing repetitive neuronal firing. It also inhibits carbonic anhydrase, which may contribute to its anticonvulsant effects. These combined mechanisms suppress abnormal electrical activity in the brain, making it effective for seizure control.
Approved indications
- Epilepsy (adjunctive therapy for partial seizures)
- Generalized tonic-clonic seizures
Common side effects
- Somnolence
- Ataxia
- Dizziness
- Anorexia
- Weight loss
- Cognitive impairment
- Nephrolithiasis
- Hypohidrosis
Key clinical trials
- Noise-Induced Hearing Loss-Acute Exposure Treatment (UA) (PHASE2)
- A Clinical Study on the Efficacy and Safety of Zonisamide as a First Add-On Treatment in Epileptic Seizures (PHASE4)
- Noise-Induced Hearing Loss-Acute Exposure Treatment (PHASE2)
- Role of Zonisamide in Advanced Parkinson's Disease (PD) in Egyptian Population: Pilot Study (NA)
- Zonisamide Treatment of Alcohol Use Disorder: an Evaluation of Efficacy and Mechanism of Action (PHASE3)
- Effectiveness of Zonisamide in Alcohol Dependent Veterans (PHASE3)
- Characterization of Epilepsy Patients BEEP 2b (PHASE1)
- A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral Zonisamide Therapy CI brief — competitive landscape report
- Oral Zonisamide Therapy updates RSS · CI watch RSS
- Affiliated Hospital of Nantong University portfolio CI